Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18430378 | METHOD FOR PRECISELY PREPARING CIRCULAR RNA WITH ANABAENA INTRON SELF-CLEAVING RIBOZYME | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18483663 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | October 2023 | October 2024 | Allow | 12 | 2 | 0 | No | No |
| 18320948 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | May 2023 | March 2025 | Allow | 22 | 0 | 0 | No | No |
| 18185929 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | March 2023 | November 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18176868 | BUILDING DESIGNER RNA NANO-STRUCTURES FOR SYNTHETIC BIOLOGY APPLICATIONS | March 2023 | June 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18145218 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | December 2022 | March 2025 | Allow | 27 | 1 | 0 | No | No |
| 18067686 | TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEM | December 2022 | March 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 17924966 | OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | November 2022 | March 2025 | Allow | 28 | 1 | 1 | No | No |
| 17985683 | MATERIALS AND METHODS FOR THE DELIVERY OF THERAPEUTIC NUCLEIC ACIDS TO TISSUES | November 2022 | April 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18054264 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | November 2022 | April 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17978295 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | November 2022 | March 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17978490 | MICRORNA-BASED LOGIC GATES AND USES THEREOF | November 2022 | February 2025 | Allow | 27 | 1 | 0 | No | No |
| 17972299 | IN VITRO NEPHROTOXICITY SCREENING ASSAY | October 2022 | March 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18047723 | COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE | October 2022 | March 2025 | Abandon | 29 | 1 | 0 | Yes | No |
| 18046108 | RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use | October 2022 | March 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17895615 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | August 2022 | January 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17888084 | miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME | August 2022 | June 2025 | Abandon | 34 | 2 | 1 | Yes | No |
| 17813576 | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION | July 2022 | January 2025 | Allow | 30 | 0 | 0 | No | No |
| 17863984 | METHODS RELATING TO CIRCULATING TUMOR CELL CLUSTERS AND THE TREATMENT OF CANCER | July 2022 | December 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17864199 | RIG-I AGONISTS AND METHODS USING SAME | July 2022 | June 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17811593 | PHOSPHORYLATION-BASED MIRNA SENSOR | July 2022 | February 2025 | Allow | 31 | 1 | 0 | No | No |
| 17848850 | MODIFIED RNAi AGENTS | June 2022 | December 2024 | Allow | 30 | 1 | 0 | No | No |
| 17847770 | NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, PREPARATION METHOD AND USE THEREOF | June 2022 | April 2025 | Allow | 34 | 2 | 0 | No | No |
| 17806879 | DEAMINASE-BASED RNA SENSORS | June 2022 | September 2024 | Allow | 27 | 3 | 1 | No | No |
| 17804280 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | May 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17727263 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | April 2022 | December 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17725102 | DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS | April 2022 | August 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17705609 | CELL-SPECIFIC EXPRESSION OF modRNA | March 2022 | October 2024 | Allow | 30 | 2 | 0 | No | No |
| 17706522 | COMPOSITIONS AND PROCESSES FOR TARGETED DELIVERY, EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS IN TISSUE | March 2022 | November 2024 | Allow | 32 | 3 | 1 | Yes | No |
| 17688985 | HIGH PERFORMANCE MULTI-INPUT MICRORNA SENSORS AND USES THEREOF | March 2022 | January 2025 | Allow | 34 | 2 | 0 | No | No |
| 17678433 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS | February 2022 | July 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17580269 | O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES | January 2022 | January 2025 | Allow | 35 | 2 | 0 | No | Yes |
| 17549817 | IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE | December 2021 | April 2025 | Abandon | 40 | 2 | 1 | Yes | Yes |
| 17497571 | Bruton's Tyrosine Kinase as Anti-Cancer Drug Target | October 2021 | December 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17319744 | SARNA COMPOSITIONS AND METHODS OF USE | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | Yes |
| 17293065 | CXCL8 Binding Nucleic Acids | May 2021 | March 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 17308572 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | May 2021 | June 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17213852 | SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | March 2021 | October 2023 | Allow | 31 | 3 | 1 | Yes | Yes |
| 17280454 | RECOMBINANT TYPE I CRISPR-CAS SYSTEM AND USES THEREOF FOR SCREENING FOR VARIANT CELLS | March 2021 | September 2024 | Allow | 42 | 2 | 0 | No | No |
| 17181142 | METHOD FOR DETERMINING DECREASE IN FUNCTIONS OF HIPPOCAMPUS BY USING CORRELATION BETWEEN MICRO RNA AND NMDA RECEPTOR, METHOD FOR INHIBITING DECREASE IN FUNCTIONS, AND METHOD FOR SCREENING FOR INHIBITORS OF DECREASE IN FUNCTIONS | February 2021 | March 2025 | Allow | 49 | 2 | 0 | No | No |
| 17177747 | COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES | February 2021 | April 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17252050 | APPLICATION OF NIEMANN-PICK C1 PROTEIN IN DIAGNOSIS AND TREATMENT OF CANCER | December 2020 | April 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17115791 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | December 2020 | November 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17084460 | Sequence Multiplicity Within Spherical Nucleic Acids | October 2020 | April 2025 | Allow | 53 | 3 | 1 | No | No |
| 17072056 | COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | October 2020 | January 2025 | Abandon | 51 | 1 | 1 | No | No |
| 16967102 | APPLICATION OF APTAMER IN RECOGNITION AND BINDING OF ALKALINE PHOSPHATASE HETERODIMER OR TUMOR DETECTION | August 2020 | March 2025 | Allow | 55 | 2 | 1 | No | No |
| 16966840 | METHODS FOR THERAPEUTIC USE OF EXOSOMES AND Y-RNAS | July 2020 | July 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 16961578 | ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF | July 2020 | October 2024 | Allow | 52 | 2 | 0 | No | No |
| 16878409 | TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT | May 2020 | September 2022 | Allow | 28 | 3 | 1 | No | Yes |
| 16870960 | MODIFIED PLURIPOTENT CELLS | May 2020 | October 2024 | Allow | 53 | 4 | 1 | Yes | No |
| 16642244 | METHODS AND COMPOSITIONS FOR APTAMER-DRIVEN SURFACE FORMULATION OF SELF-FORMING POLYNUCLEOTIDE NANOPARTICLES | February 2020 | November 2024 | Abandon | 56 | 1 | 1 | No | No |
| 16494279 | CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR VIRUS DETECTION | September 2019 | September 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16316298 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | January 2019 | February 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16100906 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | August 2018 | May 2019 | Allow | 10 | 0 | 0 | No | No |
| 15886386 | NOTCH 1 SPECIFIC siRNA MOLECULE | February 2018 | January 2020 | Allow | 24 | 1 | 1 | No | No |
| 15743988 | METHOD OF PRODUCING RNA FROM CIRCULAR DNA AND CORRESPONDING TEMPLATE DNA | January 2018 | July 2019 | Allow | 18 | 1 | 1 | No | No |
| 15814353 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING | November 2017 | March 2020 | Allow | 28 | 3 | 0 | Yes | Yes |
| 15533965 | Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides | September 2017 | March 2025 | Allow | 60 | 6 | 1 | No | No |
| 15685983 | INHIBITORS OF MYH7B AND USES THEREOF | August 2017 | July 2018 | Allow | 11 | 0 | 1 | No | No |
| 15543728 | NUCLEIC ACID NANOSTRUCTURES WITH CORE MOTIFS | July 2017 | February 2020 | Allow | 31 | 2 | 1 | No | No |
| 15543513 | METHOD FOR SELECTING SKELETAL MUSCLE PROGENITOR CELL | July 2017 | January 2020 | Allow | 30 | 3 | 0 | Yes | No |
| 15601170 | BIOTIN COMPLEXES FOR TREATMENT AND DIAGNOSIS OF ALZHEIMER'S DISEASE | May 2017 | August 2019 | Allow | 27 | 2 | 1 | Yes | No |
| 15383600 | MODULATION OF HUMAN CYTOMEGALOVIRUS REPLICATION BY MICRO-RNA 132 (miR132), MICRO-RNA 145 (miR145) AND MICRO-RNA 212 (miR212) | December 2016 | October 2018 | Allow | 22 | 2 | 1 | No | No |
| 15305058 | METHODS FOR ENHANCING OR DECREASING THE LEVELS OF MIR124 AND MIR29 IN SUBJECTS WITH MUSCULAR DYSTROPHY | October 2016 | August 2018 | Allow | 22 | 2 | 1 | Yes | No |
| 15034529 | USE OF IKK EPSILON INHIBITORS TO ACTIVATE NFAT AND T CELL RESPONSE | May 2016 | March 2019 | Allow | 34 | 2 | 1 | No | No |
| 14783078 | Mutations in DSTYK Cause Dominant Urinary Tract Malformations | October 2015 | September 2018 | Allow | 35 | 1 | 1 | No | No |
| 14761083 | METHOD FOR INHIBITING TUMOR GROWTH THROUGH RNA-INTERFERENCE USING LIPOSOMALLY ASSOCIATED CDC20 siRNA | July 2015 | October 2018 | Allow | 39 | 4 | 1 | Yes | No |
| 14012302 | METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES | August 2013 | March 2014 | Allow | 6 | 1 | 0 | No | No |
| 13470154 | TREATMENT OF INFLUENZA | May 2012 | December 2013 | Allow | 19 | 2 | 1 | Yes | No |
| 13457394 | MODIFIED SIRNA MOLECULES AND USES THEREOF | April 2012 | April 2013 | Allow | 12 | 1 | 0 | No | No |
| 13323461 | PROINFLAMMATORY NUCLEIC ACIDS | December 2011 | July 2013 | Allow | 19 | 1 | 0 | No | No |
| 13290609 | SYNTHETIC GENES AND GENETIC CONSTRUCTS | November 2011 | December 2012 | Allow | 14 | 1 | 0 | No | No |
| 13274730 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-146a | October 2011 | November 2012 | Allow | 13 | 1 | 0 | No | No |
| 13274719 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-221 | October 2011 | November 2012 | Allow | 13 | 1 | 0 | Yes | No |
| 13274737 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-125B | October 2011 | October 2012 | Allow | 12 | 1 | 0 | Yes | No |
| 13274724 | METHOD FOR DIAGNOSING ACUTE LYMPHOMIC LEUKEMIA (ALL) USING MIR-222 | October 2011 | October 2012 | Allow | 12 | 1 | 0 | Yes | No |
| 13269407 | MIR-182-, MIR-191, MIR-199A-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) | October 2011 | January 2013 | Allow | 15 | 2 | 0 | No | No |
| 13269410 | MIR-25-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) | October 2011 | November 2012 | Allow | 13 | 2 | 0 | No | No |
| 13269404 | MIR-29-BASED METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) | October 2011 | May 2013 | Allow | 19 | 3 | 0 | No | No |
| 13245180 | HUMAN SERUM ALBUMIN-SIRNA NANO-SIZED CARRIER SYSTEM | September 2011 | April 2013 | Allow | 19 | 1 | 0 | No | No |
| 13084772 | STRESS-RESPONSIVE INDUCTION OF A THERAPEUTIC AGENT AND METHODS OF USE | April 2011 | October 2012 | Abandon | 18 | 1 | 0 | No | No |
| 13039100 | INHIBITION OF VIRAL GENE EXPRESSION USING SMALL INTERFERING RNA | March 2011 | January 2013 | Allow | 23 | 2 | 1 | No | No |
| 13031522 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING | February 2011 | March 2012 | Allow | 13 | 1 | 0 | No | No |
| 12947865 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | November 2010 | August 2012 | Allow | 21 | 0 | 0 | No | No |
| 12858892 | THERAPEUTIC AGENT FOR NEUROBLASTOMA TARGETING ARID3B | August 2010 | October 2011 | Allow | 14 | 0 | 0 | No | No |
| 12835333 | NUCLEOLAR TARGETING OF THERAPEUTICS AGAINST HIV | July 2010 | March 2012 | Allow | 20 | 3 | 0 | No | No |
| 12799758 | SIRNA TARGETING INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4(IRAK4) | April 2010 | March 2012 | Allow | 23 | 2 | 1 | No | No |
| 12305637 | RESTORATION OF HEARING LOSS | April 2010 | March 2012 | Allow | 39 | 2 | 1 | No | No |
| 12666738 | TREATMENT OF INFLUENZA | March 2010 | February 2012 | Allow | 26 | 1 | 1 | No | No |
| 12704226 | ENIGMA-MDM2 INTERACTION AND USES THEREOF | February 2010 | November 2011 | Allow | 21 | 1 | 1 | No | No |
| 12700009 | COMPOSITIONS AND METHODS FOR MODULATING GHRELIN-MEDIATED CONDITIONS | February 2010 | August 2012 | Allow | 30 | 2 | 1 | No | No |
| 12651810 | EXPRESSED PSEUDOGENE REGULATES GENE EXPRESSION | January 2010 | September 2011 | Allow | 20 | 1 | 1 | No | No |
| 12649141 | HYPOXIA INDUCIBLE VEGF PLASMID FOR ISCHEMIC DISEASE | December 2009 | April 2011 | Allow | 15 | 1 | 0 | No | No |
| 12644674 | NRIP1 REGULATION OF APOLIPOPROTEIN A1 | December 2009 | April 2012 | Allow | 28 | 0 | 1 | No | No |
| 12590252 | SIRNA TARGETING AMYLOID BETA (A4) PRECURSOR PROTEIN (APP) | November 2009 | June 2010 | Allow | 8 | 0 | 1 | No | No |
| 12579323 | SHORT HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION | October 2009 | May 2012 | Allow | 31 | 2 | 1 | No | No |
| 12579259 | FAS/FASL OR OTHER DEATH RECEPTOR TARGETED METHODS AND COMPOSITIONS FOR KILLING TUMOR CELLS | October 2009 | June 2011 | Allow | 20 | 1 | 1 | Yes | No |
| 12583073 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING RETINAL DISEASES BASED ON METARGIDIN (ADAM-15) | August 2009 | December 2011 | Allow | 28 | 1 | 2 | No | No |
| 12299607 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PTP1B | July 2009 | July 2013 | Allow | 56 | 3 | 2 | Yes | No |
| 12462029 | SIRNA TARGETING INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) | July 2009 | April 2010 | Allow | 9 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHITEMAN, BRIAN A.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WHITEMAN, BRIAN A works in Art Unit 1636 and has examined 200 patent applications in our dataset. With an allowance rate of 90.5%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner WHITEMAN, BRIAN A's allowance rate of 90.5% places them in the 72% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by WHITEMAN, BRIAN A receive 2.31 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WHITEMAN, BRIAN A is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +7.2% benefit to allowance rate for applications examined by WHITEMAN, BRIAN A. This interview benefit is in the 37% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 29.6% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 57.8% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 96.4% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 92.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 63.5% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 25.5% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 14.4% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.